KT195
SIGMA/SML1308 - ≥98% (HPLC)
Synonym: [4-(4′-Methoxy[1,1′-biphenyl]-4-yl)-1H-1,2,3-triazol-1-yl](2-phenyl-1-piperidinyl)-methanone
CAS Number: 1402612-58-1
Empirical Formula (Hill Notation): C27H26N4O2
Molecular Weight: 438.52
Linear Formula: C27H26N4O2
Product Type: Chemical
This image is provided for informative purposes only and does not represent an actual product label. It should not be used as a substitute for official product labeling.
| assay | ≥98% (HPLC) |
| color | white to beige |
| form | powder |
| InChI | 1S/C27H26N4O2/c1-33-24-16 |
| InChI key | OEHLNQDRVMDXQD-UHFFFAOYSA |
| Quality Level | 100  |
| SMILES string | [n]3(nnc(c3)c4ccc(cc4)c5c |
| solubility | DMSO: 5 mg/mL, clear (warmed) |
| storage temp. | 2-8°C |
| Biochem/physiol Actions: | KT195 is a potent (IC50 = 10 nM) and selective inhibitor of α/β-hydrolase domain-containing 6 (ABHD6). |
| Biochem/physiol Actions: | KT195 is a potent (IC50 = 10 nM) and selective inhibitor of α/β-hydrolase domain-containing 6 (ABHD6), a serine hydrolase that acts as an alternative hydrolase of the endocannabinoid 2-arachidonoylglycerol (2-AG). KT195 has negligible activity against other serine hydrolases such as DAGLβ and has been used as a control probe for studies of DAGLβ as well as being a probe on its own to study ABHD6. KT195 treatment of Neuro2A cells caused significant accumulation of 2-AG. KT195 also lowered interleukin-1β (IL-1β) secretion from lipopolysaccharide-treate |
| Packaging: | 5, 25 mg in glass bottle |
| Symbol |  GHS06 |
| Signal word | Danger |
| Hazard statements | H301 - H413 |
| Precautionary statements | P273 - P301 + P310 + P330 |
| RIDADR | UN 2811 6.1 / PGIII |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |